Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Where in United States
- Boston · Dana Farber Cancer CenterUnknown status
- Nashville · Sarah Cannon Research InstituteUnknown status
- New York · Memorial Sloane Ketterin Cancer CtrUnknown status
- Tampa · H Lee Moffitt Cancer Center and Research InstituteUnknown status
Also in 8 other countries, 11 sites
Spain 3, Netherlands 2, Canada 1, Italy 1, Japan 1, Singapore 1, South Korea 1, Taiwan 1.
The registry text, word for word
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
Inclusion: Able to understand and voluntarily sign the ICF and able to comply with the study visit schedule and the other protocol requirements; Patient (male or female) ≥18 years of age willing to agree to not father a child/become pregnant and comply with effective contraception criteria; Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or is appropriate; ECOG (Eastern cooperative oncology group) performance status ≤2; Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):; Patients must be screened for Hepatitis B virus and Hepatitis C virus.
Exclusion: Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use at the time of study entry; Patients who have undergone a bone marrow or solid organ transplant; Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures; Clinically significant cardiac disease; Active diarrhea or inflammatory bowel disease; Patients with a known history of human immunodeficiency virus (HIV) seropositivity; Patients with a history or presence of interstitial lung disease or interstitial pneumonitis; Bullous and exfoliative skin disorders at screening of any grade; Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations. (Exceptions are KRAS G12-mutant NSCLC's); History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO; Insufficient bone marrow function; Insufficient hepatic and renal function; Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):; Presence of clinically significant ophthalmological abnormalities that might increase the risk of corneal epithelial injury.